NASDAQ:SNDXSyndax Pharmaceuticals Stock Price, Forecast & News

Syndax Pharmaceuticals' stock was trading at $11.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SNDX shares have increased by 43.3% and is now trading at $16.89. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syndax Pharmaceuticals.

Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Syndax Pharmaceuticals.

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.05. The company earned $0.38 million during the quarter, compared to the consensus estimate of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 132.06% and a negative net margin of 4,013.65%. View Syndax Pharmaceuticals' earnings history.

9 Wall Street analysts have issued 12 month target prices for Syndax Pharmaceuticals' shares. Their forecasts range from $14.00 to $33.00. On average, they expect Syndax Pharmaceuticals' share price to reach $21.38 in the next year. This suggests a possible upside of 26.6% from the stock's current price. View analysts' price targets for Syndax Pharmaceuticals.

News headlines about SNDX stock have been trending somewhat positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutSyndax Pharmaceuticals.

Some companies that are related to Syndax Pharmaceuticals include Ra Pharmaceuticals (RARX), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), Pacira Biosciences (PCRX), Ligand Pharmaceuticals (LGND), Eidos Therapeutics (EIDX), IGM Biosciences (IGMS), SAGE Therapeutics (SAGE), Passage Bio (ZNTL), Epizyme (EPZM), Zymeworks (ZYME), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH) and Heron Therapeutics (HRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), Verastem (VSTM), Micron Technology (MU), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), Clearside Biomedical (CLSD), Idera Pharmaceuticals (IDRA), Novavax (NVAX) and TG Therapeutics (TGTX).

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (8.31%), BlackRock Inc. (7.96%), Frazier Management LLC (2.74%), Aisling Capital Management LP (2.89%), State Street Corp (1.22%) and Geode Capital Management LLC (0.92%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison and Michael L Meyers. View institutional ownership trends for Syndax Pharmaceuticals.

SNDX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Wells Fargo & Company MN, Morgan Stanley, UBS Group AG, Nuveen Asset Management LLC, Ensign Peak Advisors Inc, Parametric Portfolio Associates LLC, and State Street Corp. View insider buying and selling activity for Syndax Pharmaceuticals.

SNDX stock was acquired by a variety of institutional investors in the last quarter, including Frazier Management LLC, Aisling Capital Management LP, BlackRock Inc., Ghost Tree Capital LLC, Eventide Asset Management LLC, Russell Investments Group Ltd., Orbimed Advisors LLC, and Sphera Funds Management LTD.. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison, and Michael L Meyers. View insider buying and selling activity for Syndax Pharmaceuticals.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SNDX stock can currently be purchased for approximately $16.89.

Syndax Pharmaceuticals has a market capitalization of $609.64 million and generates $1.52 million in revenue each year. The company earns $-56,050,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.

The official website for Syndax Pharmaceuticals is www.syndax.com.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]